New Zealand government invests $604 million in Pharmac, expanding cancer treatment access.

New Zealand's government has invested $604 million in Pharmac, enhancing access to cancer treatments for its citizens. This funding allows full coverage for Cetuximab from November 1, 2024, aiding 380 bowel cancer patients. Pembrolizumab (Keytruda) will be funded starting October 1, and eligibility for chemotherapy drugs bendamustine and pemetrexed has been broadened. Associate Health Minister David Seymour highlighted the government's commitment to a patient-centered healthcare approach.

October 09, 2024
9 Articles